Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer

Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot
for TAR-1, a Novel Therapeutic for the Treatment of Cancer
Champions Biotechnology Building Tumorgraft-Driven Oncology Drug Pipeline

BALTIMORE, Oct. 27 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc.
(OTC Bulletin Board: CSBR), an oncology drug development company with a
predictive preclinical platform aimed at accelerating the development and
enhancing the value of oncology drugs, has established an exclusive licensing
agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly
owned technology transfer company. The licensing agreement encompasses the
development and commercialization of TAR-1, a single-chain antibody fragment
in preclinical development that may have an advantage in treating cancer
patients because of its high specificity and affinity to binding mutant p53
protein.

Under the terms of the agreement, Champions has obtained the worldwide rights
to TAR-1 and is responsible for the further development of the compound.
Champions will utilize its Biomerk Tumorgraft(TM) platform technology to
evaluate the activity of TAR-1 and determine the best path forward for the
compound in regards to indication, patient population and potential drug
combinations. Ramot will receive an upfront payment and will be eligible to
receive milestone payments and royalties if Champions chooses to continue the
license terms, which will be determined based on results from testing TAR-1 in
the predictive Tumorgraft platform.

Prof. Beka Solomon from Tel Aviv University identified that TAR-1 binds to and
restores the wild-type active conformation of mutant p53 protein with a high
degree of specificity, leading to in vivo inhibition of tumor growth. Given
the frequency of mutant p53 in cancer, TAR-1 has the potential to target a
wide range of human cancers.

"Licensing TAR-1 demonstrates the progression of our strategy to build our own
Tumorgraft-driven pipeline of oncology drugs, which we expect to yield
improved clinical development success rates," said Guy Malchi, Champions
Biotechnology's Head of Corporate Development and International Operations.
"We were impressed by the potential of TAR-1 and we are planning to continue
to in-license oncology drug candidates with compelling science and to develop
only those with positive Tumorgraft results." TAR-1 will undergo Tumorgraft
testing as Champions completes Tumorgraft testing of its other oncology drug,
SG410, a tubulin inhibitor.

"We are excited to work with Champions Biotechnology. Their predictive
platform and experienced scientific and clinical team make them an ideal
candidate to move TAR-1 forward into the clinic and on the path to
commercialization," said Dr. Ze'ev Weinfeld, CEO, Ramot at Tel Aviv University
Ltd.

For more information regarding Champions Biotechnology's growing business and
recent news, please visit www.championsbiotechnology.com.

About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and tumor specific data to enhance and accelerate the
value of oncology drugs. The Company's Preclinical Platform is a novel
approach based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological characteristics of
the original human tumor. Early studies suggest that unlike traditional
xenografts, these Tumorgrafts closely reflect human cancer biology and their
response to drugs is predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic candidates. As
drugs progress through early stage development, the Company plans to sell,
partner or license them to pharmaceutical and/or biotechnology companies, as
appropriate. The Company also offers its predictive preclinical platform and
tumor specific data to physicians for personalized patient care and to
companies for evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.

www.championsbiotechnology.com

www.personalizedcancertreatment.com

Ramot at Tel Aviv University Ltd.
Ramot at Tel Aviv University Ltd. is the technology transfer company of Tel
Aviv University (TAU). Ramot fosters, initiates, leads and manages the
transfer of new technologies from university laboratories to the marketplace
by performing all activities relating to the protection and commercialization
of inventions and discoveries made by faculty, students and other researchers.
Ramot provides a dynamic interface connecting industry to leading edge science
and innovation, offering new business opportunities in a wide variety of
emerging markets. Founded in 1956, TAU is one of Israel's foremost research
and teaching universities. Located in Israel's cultural, financial and
industrial heartland, TAU is at the forefront of basic and applied research in
a wide variety of scientific research disciplines.

www.ramot.org

This press release contains "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect," "anticipate," "plan,"
and similar expressions to identify forward-looking statements. One should not
place undue reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the forward-looking
statements for many unforeseen factors. See Champions Biotechnology's Form
10-K for the fiscal year ended April 30, 2009 for a discussion of such risks,
uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.

MEDIA CONTACTS:

The Investor Relations Group
James Carbonara
+1-212-825-3210

Yamit Nissnaov, PR for Ramot
Office: +972-9-9514666
Mobile: +972-52-5541810
Email: yamit@idancom.com

SOURCE Champions Biotechnology, Inc.

The Investor Relations Group: James Carbonara, +1-212-825-3210; or Yamit
Nissnaov, PR for Ramot, Office: +972-9-9514666, or Mobile: +972-52-5541810,
yamit@idancom.com